Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"In the ibox on fda plays"
Could you provide the link please, I do not know where that is.
Thanks
Sorry I cant remember where I found that target price but I did find this..Here is the company we have partnered with to sell in europe.. http://www.astellas.us/about/profile/
Found this one...Ladenburg Thalmann Analysts Raise Price Target on Optimer Pharmaceutic (OPTR) Shares to $16.00
April 8th, 2011 • View Comments • Filed Under • by ABMN Staff
And read this!! Antibiotic-associated (C. difficile) colitis is an infection of the colon caused by C. difficile that occurs primarily among individuals who have been using antibiotics. It is the most common infection acquired by patients while they are in the hospital. More than three million C. difficile infections occur in hospitals in the US each year. After a stay of only two days in a hospital
Yes check post 83 and I will locate where I read that.
In the ibox on fda plays you will see tons of tickers for bio/pharma companies.I researched all of them.Found about 6 that look good but the news coming for optr put it over the top for me.
Any particular web site that is particularly good for researching or getting good info on Biotechs ?
Thanks
This should start moving up towards the 5/30 approval. Any target prices before and after approval if it goes through.
I litteraly did research on 41 different bio/pharma/therapeutic companies last night for hours and found nothing as exciting as OPTR for a buy opportunity.I bought OPTR last week and will buy more on monday.
Cdif is a major worldwide problem every hospital and nursing home will want an effective cdif medication.Also my wife who is an RN now has to do mandatory cdif training where all hospital personel must complete and pass.
dont like how high the stock has run sinse september but still see some run room for it.Wish I would have found this one earlier!!!
I added to my position as well. I am expecting pps to approach 15 prior to PDUFA date and 17 or so post approval.
Bought various sized lots all day, managed to average-down to $12.26.
The downside, of course, is that I now have a much bigger position than I originally intended, but I feel confident going into approval.
Best of luck to all.
Just averaged down, good-sized lot at $12.17.
Best of luck to all.
Yes I know what you mean it went down about 5 minutes after I decided to buy. I guess whatever it does today is what matters. Usually they run high at the opening of PM and then settle down later on.
Exactly, that's why I'm hesitating and probably won't take the bait. I've been burnt in the past by doing that.
The other side of the coin, of course, is when at 9:30 the stock takes off right out of the gate and never looks back.
I must admit, I'm still ticked-off about yesterday. I waited until almost 3:00 to buy when the PPS looked fairly stable. I had to leave for an hour or so, got back about 4:15, looked at the closing price and almost fell over!
The ask is pretty high. See what it opens at in about 27 minutes. PM trading can fluctuate a lot.
I've got a sizable pre-market order in at $12, but it doesn't look like it will be filled. Currently @ $12.22.
Trying to decide whether to bump it up or not.
Excellent earnings. I would buy more before this moves up IMO. Most likely they will receive approval IMO on 5/30 which is coming up fast.
next wednesday, ASCO abstracts will be available (i think), so once again those participants and most-small-cap bio will be hot or up or whatever... (in my opinion only!)
http://www.prnewswire.com/news-releases/optimer-pharmaceuticals-reports-first-quarter-2011-financial-results-121346888.html
SAN DIEGO, May 5, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced its financial results for the quarter ended March 31, 2011.
Optimer reported net income for the first quarter of 2011 of $45.1 million, or $1.06 and $1.04 per basic and diluted share, respectively, as compared to a net loss for the first quarter of 2010 of $13.5 million, or ($0.39) per share on both a basic and diluted basis. The increase in net income was primarily due to licensing revenue from a $69.2 million upfront payment received from Astellas Pharma in connection with the DIFICID™ collaboration and license agreement. The increase was partially offset by a $10.4 million increase in operating expenses, including $4.3 million in licensing costs due to a royalty payment to Par Pharmaceutical associated with the Astellas upfront payment.
In addition, marketing expenses for the first quarter of 2011 increased $3.2 million compared to the prior year period due to market research and pre-commercialization efforts related to the DIFICID program. General and administrative expenses increased $5.9 million compared to the first quarter of 2010 due to increases in consulting expenses and advisory fees related to DIFICID collaborations, increases in compensation expense, including a $1.0 million increase in stock compensation expense, and increased headcount, including the establishment of a market access team. Research and development expenses decreased $2.9 million compared to the first quarter of 2010 due to a $5.0 million milestone payment in the prior year due to Par for the successful completion of the second DIFICID Phase 3 trial offset by an increase in medical affairs and publication expenses.
As of March 31, 2011, Optimer held cash, cash equivalents and short-term investments of $180.1 million.
"Optimer was extremely productive in the first quarter of 2011. We participated in a highly successful FDA Advisory Committee meeting, wherein we secured a unanimous vote supporting the safety and efficacy of DIFICID for the treatment of CDI. We also entered into collaboration agreements with Astellas in Europe and other countries to market DIFICID and with Cubist in the U.S. to co-promote DIFICID. We believe this will help us maximize the impact of a potential DIFICID commercial launch," said Pedro Lichtinger, President and CEO of Optimer. "We continue to work with the FDA as it considers our DIFICID NDA and we look forward to the FDA's decision on our NDA by the May 30th PDUFA date. Meanwhile, we are continuing to build our commercial team and marketing program with the goal of positioning for a successful product launch pending FDA approval."
First Quarter and Recent Corporate Highlights
* U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee recommended in a unanimous 13-0 decision, that the FDA approve DIFICID for the treatment of patients with Clostridium difficile infection (CDI). While the advisory committee vote was split on how best to describe the recurrence benefit, the committee members overwhelmingly recognized that DIFICID at 30 days after treatment was superior to vancomycin. The FDA has assigned a Prescription Drug User Fee Act goal date of May 30, 2011.
* Announced co-promotion agreement with Cubist Pharmaceuticals to market DIFICID for the treatment of CDI in the U.S. In an effort to accelerate the rate of launch of DIFICID, if approved, Optimer and Cubist will co-promote DIFICID to physicians, hospitals, long-term care facilities and other healthcare institutions and will also jointly provide medical affairs support for the product.
* Announced collaboration with Astellas Pharma Europe Ltd. to develop and commercialize DIFICID for the treatment of CDI in Europe and certain other countries in the Middle East, Africa, and the Commonwealth of Independent States. Optimer received a $69.2 million upfront cash payment and is eligible to receive milestone payments of up to approximately 115.0 million Euros and tiered double-digit royalty payments on net sales of DIFICID in the territory.
* Raised $73.1 million in net proceeds in a public offering of common stock in February 2011.
* Strengthened the management team in preparation for the potential commercial launch of DIFICID with the appointments of Nancy M. Ruiz, M.D., as Senior Vice President of Research and Development, Cynthia Schwalm, as Senior Vice President of International, Kasia Petchel, M.D., as Senior Vice President of Pharmacovigilance, and Glenn Tillotson, Ph.D., as Senior Vice President of Medical Affairs. Optimer also made two significant promotions, consisting of the promotion of Sherwood Gorbach, M.D. to the position of Chief Scientific Officer and Senior Vice President, and the promotion of Marc Lesnick, Ph.D., to Vice President of Regulatory Affairs.
* DIFICID North American Phase 3 trial results were published in The New England Journal of Medicine in an article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile infection," in the February 3, 2011 issue.
* Two DIFICID patents were issued by the U.S. Patent and Trademark Office, one which covers methods of CDI treatment with DIFICID and one which covers additional dosage forms of DIFICID. Both patents are eligible for listing in the FDA's Orange Book.
* Announced appointment of former Chief Executive Officer and Chairman of the Board of Directors of Pfizer, Hank McKinnell, Ph.D. to Optimer's Board of Directors.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID™ (fidaxomicin) and Pruvel™ (prulifloxacin). DIFICID is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of the NDA for DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for DIFICID. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Forward-looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the development and potential approval and commercialization of DIFICID, the expected benefits of and activities under Optimer's collaboration and co-promotion agreements, the timing of any review of regulatory submissions, and the potential payment of milestones or royalties by Astellas. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: whether the FDA or other regulatory authorities will meet their goals for reviewing Optimer's regulatory submissions, whether Optimer will receive regulatory approval for DIFICID, the fact that the FDA may not follow the advice of the Advisory Committee with respect to the approval of DIFICID, Optimer's ability to recognize anticipated benefits from its collaborations with Astellas and Cubist, the costs and timing of commercializing DIFICID in the U.S., if approved, potential labeling restrictions on DIFICID, if approved, the ability of Optimer and its collaboration partners to successfully commercialize DIFICID, if approved, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.
Thanks kei always enjoy reading your posts.
I am really excited about OPTR
good luck to you tomorrow!
btw, my astm and aezs are down at the end also...the same intraday chart..
OPTR: Bought in yesterday and mid-afternoon today, very surprised by the end-of-day drastic drop.
The earnings report looks fine, they're in the green, looks like they're getting stuff together in prep for approval.
My only concern is the recurrence wording on the label, hopefully they'll work out a satisfactory compromise with the FDA.
If I get the chance tomorrow, I'll average-down under $12.
Best of luck to all.
i don't know if you know but last year we had correction before asco in june...prior to correction (before asco), we had so much fun! bio-techs were so hot!
however, good thing for optr is we are waiting for the fda decision not asco.
good luck to you, braden!
Just finished reading the entire pr and this company is doing everything right.TIME TO BUY!!!!!!!
I bet everyone is just sick to there stomachs and havnt looked at the news yet.Tomorrow should be fun.But the way the market has been lately ya never know,
It is moving up but ah is slower Man Im feeling good now.....They were expecting aloss this qtr
Yes it does I'm surprised it's not moving AH. Actually it's up from it's close and ask is moving up quick.
LOL I missd those two but it looks like OPTR will pay off.
I had an adventure with SPPI and NEOP this week if you've been following that. And now I am in this one which went down about 5 minutes after I bought it. Something good has to happen soon.
1st Q income of 45 mil. 1.04 pr share
Maybe fda news comes soon or some kinda good news.
Im kinda sick to stomach from this one today.
BUT AMR has done me well this week.
Looked like a mini Bear Raid at the EOD. Good news maybe?
Just trying to be positive. Probably not the way this week has been going. I hate stocks!
Clostridium difficile infection, or CDI is a bacterial infection in the lining of the gut that can cause severe diarrhea, colitis and in some cases death. In the U.S. alone, CDI is said to infect 700,000 people each year.
Optimer's Dificid is a new antibiotic with a novel mechanism of action, which inhibits the bacterial enzyme RNA polymerase, resulting in the rapid killing of C. difficile.
I see a downward trend in the chart and it appears that we may have bottomed.Cmon news....
I see OPTR at 17+ range upon approval easily. C diff is a serious issue and OPTR drug prevents relapse which is key differentiator from VPHM's vanco. I see OPTR's drug grabbing Vanco's market share rapidly...
This out today....
A 32.2% potential upside exists for Optimer Pharmaceuticals, based on a current level of $12.63 and analysts' average consensus price target of $16.70.
Wow, simply Awesome!
Great summary. Thanks and have a nice weekend!
Tim
OPTR
OPTR: On Watch for entry in next week~
Thanks for nice DD!!
Tim
OPTR
Joined the party with OPTR today. GLTA!
Agree...expect to be 15+ around that date with 18+ upon approval. Panel vote has been very positive..
I hope so. I expect OPTR to move up as its May 30 PDUFA approaches.
Are we going to make it to 13 today? There seems to be a lot of acton in the last few minutes.
I bought more (adding to my core holdings). Expecting renewed surge going into end of May with 15+ prior to PDUFA date. Post approval expecting 18+ range easily. Remember their drug avoids relapses which is going to beat vanco in getting market share.
PDUFA date May 30, 2011 for Fidaxomicin for the treatment of Clostridium difficile infection.
Anybody still in this company? JUST CAN'T GET Any legs. Just seems to be be moving sideways.
with overwhelming panel vote, approval is almost certain. I expct OPTR to climb to 15+ range and upon approval into 18+. 6 months target is 20+
this one looks to be trading in a nice channel since last August. Any takers on this yet?
7:01AM Optimer Pharma and Cubist (CBST) to collaborate to co-promote DIFICID for CDI in the US (OPTR) 13.80 : Co and Cubist announced the signing of an exclusive two-year co-promotion agreement to market DIFICID, in the US. Co notes that on April 5, 2011, the FDA's Anti-Infective Drugs Advisory Committee voted unanimously that the clinical evidence submitted by Optimer demonstrated the safety and effectiveness of DIFICID for the treatment of CDI. FDA is expected to complete its review of DIFICID and deliver a decision on market approval by a PDUFA date of May 30, 2011. Under the terms of the agreement, OPTR and CBST will co-promote DIFICID to physicians, hospitals, long-term care facilities and other healthcare institutions in the US. OPTR and CBST will also jointly provide medical affairs support for the product. The agreement expires two years from the first commercial sale of DIFICID. "Optimer plans to hire 100 sales representatives to target the 1,100 hospitals, which comprise about 70% of U.S. hospital CDI cases."
Why is trading still halted ? news has been out for over an hour.
Panel voted 13-0 that fidaxomicin is safe and effective
* Panel divided on infection recurrence finding
SILVER SPRING, Md. , April 5 (Reuters) - Optimer Pharmaceuticals Inc's (OPTR.O) experimental antibiotic is safe and effective in treating a bacterial infection that causes diarrhea, a U.S. advisory panel said on Tuesday.
The advisory panel of 13 independent experts voted unanimously that the drug was effective but said there were concerns regarding the drug's use in pregnant women and children.
However, the panel was divided on whether the oral drug, fidaxomicin, was also effective in lowering the risks of recurrence of infection-related diarrhea.
Last week, the U.S. Food and Drug Administration staff said the drug was effective in fighting an infection that causes a life-threatening diarrhea. [ID:nN01111028]
The FDA is expected to give its decision on the drug by May 30. A positive vote by the panel does not guarantee an approval, but the agency usually follows panel recommendations.
The drug aims to treat diarrhea caused by C. difficile infection (CDI,) a serious illness caused by infection of the lining of the colon. It afflicts more than 700,000 people each year in the United States, according to the company.
Late-stage trials of the drug had shown that it was as effective as the only FDA-approved drug for treating CDI -- ViroPharma Inc's (VPHM.O) Vancocin.
Optimer has a deal with Japan's Astellas Pharma Inc (4503.T) on the drug. Astellas holds the rights to develop and sell the drug in Europe and parts of the Middle East and Africa.
Trading in the company's shares was halted pending news of the panel's decision. (Reporting by Esha Dey and Lisa Richwine)
8:01AM Optimer Pharma announced that NASDAQ has halted trading of its common stock this morning (OPTR) 13.78 : The Anti-Infective Drugs Advisory Committee of the FDA is scheduled to meet today to review and discuss Optimer's New Drug Application for fidaxomicin for the treatment of Clostridium difficile infection.
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
320
|
Created
|
08/23/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |